Mylan Nv Ord Shs (MYL)

Download button icon Download

Mylan Nv Ord Shs (MYL): Signals

No data currently available.


Explore Compare Share


Mylan Nv Ord Shs (MYL)



Signal Strength: MEDIUM

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.

Mylan Nv Ord Shs (NASDAQ:MYL) current pivot point Camarilla is: $31.167.

The current resistance levels are: (R1) $33.367
(R2) $35.965
(R3) $38.562
(R4) $46.354

The current support levels are: (S1) $28.173
(S2) $25.576
(S3) $22.978
(S4) $15.187

Camarilla pivot points were discovered in 1989 by Nick Scott, a successful bond trader. The basic thesis for this strategy is a common one: That price, as most time series, has a tendency to revert to its mean.

Calculation: Camarilla Pivot Points:
1) R4 = Close + (High – Low) * 1.1/2;
2) R3 = Close + (High – Low) * 1.1/4;
3) R2 = Close + (High – Low) * 1.1/6;
4) R1 = Close + (High – Low) * 1.1/12;
5) PP = (HIGH + LOW + CLOSE) / 3;
6) S1 = Close – (High – Low) * 1.1/12;
7) S2 = Close – (High – Low) * 1.1/6;
8) S3 = Close – (High – Low) * 1.1/4;
9) S4 = Close – (High – Low) * 1.1/2;

PROFILE: Mylan Nv Ord Shs (MYL)

Stock Exchange: NASDAQ
Company: Mylan Nv Ord Shs
Ticker Codes: | MYL | NASDAQ:MYL |

About Mylan Nv Ord Shs (NASDAQ:MYL):

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; anti-retroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology, oncology, and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and Dymista, which is used for the treatment of seasonal allergic rhinitis. Further, it markets OTC products, including Cold-EEZE, Midnite, and Vivarin. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, group purchasing organizations, and government entities; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. Mylan N.V. has collaboration and license agreements with Pfizer Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., and Biocon Ltd. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Top 10:

Camarilla Pivot Points

Download button icon Download
Company Close Change (%) Volume Value Signal
IESC Ies Holdings 17.2 3.8 23,253 -0.19 BEARISH
TGLS Tecnoglass Inc 9.29 3 7,143 -0.01 BEARISH
OTIC Otonomy Inc 2.36 2.6 480,000 -0.01 BEARISH
QCRH Qcr Holdings 34.64 1.6 43,158 -0.27 BEARISH
SILC Silicom 38.09 1.2 24,821 -0.09 BEARISH
MRUS Merus NV 11.58 1 29,095 -0.44 BEARISH
RNET Rignet Inc 15.21 0.9 26,786 -0.17 BEARISH
SREV Servicesrce Intl 1.2 0.8 778,092 -0.01 BEARISH
VIA Viacom Inc 33.05 0.3 18,931 0 BEARISH
TCBK Trico Bancshares 36.42 0.2 121,100 -0.03 BEARISH
back to top